Phibro Animal Health Corp (PAHC) CEO Jack Bendheim Sells 10,000 Shares

Phibro Animal Health Corp (NASDAQ:PAHC) CEO Jack Bendheim sold 10,000 shares of the stock in a transaction on Monday, June 11th. The stock was sold at an average price of $46.46, for a total transaction of $464,600.00. Following the completion of the sale, the chief executive officer now directly owns 17,470 shares of the company’s stock, valued at approximately $811,656.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

  • On Wednesday, June 13th, Jack Bendheim sold 30,000 shares of Phibro Animal Health stock. The stock was sold at an average price of $46.44, for a total transaction of $1,393,200.00.
  • On Thursday, June 7th, Jack Bendheim sold 10,000 shares of Phibro Animal Health stock. The stock was sold at an average price of $46.47, for a total transaction of $464,700.00.
  • On Tuesday, June 5th, Jack Bendheim sold 10,000 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.87, for a total transaction of $458,700.00.
  • On Thursday, March 15th, Jack Bendheim sold 24,000 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.05, for a total transaction of $961,200.00.

Shares of Phibro Animal Health traded up $0.50, hitting $47.00, on Thursday, Marketbeat Ratings reports. The stock had a trading volume of 5,051 shares, compared to its average volume of 100,666. The company has a market capitalization of $1.89 billion, a PE ratio of 30.93, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a current ratio of 3.17, a quick ratio of 1.73 and a debt-to-equity ratio of 1.61. Phibro Animal Health Corp has a 52-week low of $32.05 and a 52-week high of $48.40.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Monday, May 7th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $209.00 million during the quarter, compared to the consensus estimate of $203.03 million. Phibro Animal Health had a net margin of 7.24% and a return on equity of 39.91%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.37 earnings per share. equities research analysts predict that Phibro Animal Health Corp will post 1.71 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 27th. Stockholders of record on Wednesday, June 6th will be paid a $0.10 dividend. The ex-dividend date of this dividend is Tuesday, June 5th. This represents a $0.40 annualized dividend and a dividend yield of 0.85%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 26.49%.

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its stake in shares of Phibro Animal Health by 2,104.6% in the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after purchasing an additional 3,641 shares during the period. Highbridge Capital Management LLC bought a new position in Phibro Animal Health during the 1st quarter valued at $214,000. Piermont Capital Management Inc. bought a new position in Phibro Animal Health during the 1st quarter valued at $223,000. Teacher Retirement System of Texas bought a new position in Phibro Animal Health during the 4th quarter valued at $224,000. Finally, Crossmark Global Holdings Inc. bought a new position in Phibro Animal Health during the 4th quarter valued at $253,000. Institutional investors and hedge funds own 48.82% of the company’s stock.

Several research firms have recently issued reports on PAHC. Credit Suisse Group increased their price objective on shares of Phibro Animal Health from $39.00 to $42.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 9th. BidaskClub upgraded shares of Phibro Animal Health from a “sell” rating to a “hold” rating in a research note on Wednesday, April 18th. Zacks Investment Research downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 10th. Finally, ValuEngine upgraded shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $38.80.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

Insider Buying and Selling by Quarter for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit